Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study
| dc.contributor.author | Uslar, Thomas | |
| dc.contributor.author | Sanfuentes, Benjamín | |
| dc.contributor.author | Olmos, Roberto | |
| dc.contributor.author | Burnier, Alberth | |
| dc.contributor.author | Böhm, Pauline | |
| dc.contributor.author | Guarda, Francisco J. | |
| dc.contributor.author | Huete, Álvaro | |
| dc.contributor.author | Mertens, Nicolás | |
| dc.contributor.author | Besa, Cecilia | |
| dc.contributor.author | Andía, Marcelo | |
| dc.contributor.author | Majerson, Alejandro | |
| dc.contributor.author | Cartes, Jaime | |
| dc.contributor.author | Tapia-Castillo, Alejandra | |
| dc.contributor.author | Carvajal, Cristian A. | |
| dc.contributor.author | Fardella, Carlos E. | |
| dc.contributor.author | Allende, Fidel | |
| dc.contributor.author | Solari, Sandra | |
| dc.contributor.author | Vaidya, Anand | |
| dc.contributor.author | Baudrand, Rene | |
| dc.coverage.spatial | Netherlands | |
| dc.date.accessioned | 2026-07-21T19:35:33Z | |
| dc.date.available | 2026-07-21T19:35:33Z | |
| dc.date.issued | 2026-06-27 | |
| dc.description.abstract | Background: Incidental adrenal adenomas are common, yet renin status is infrequently assessed in hypertensive patients. Emerging evidence supports a spectrum of renin-independent aldosterone excess associated with adverse cardiovascular risk. Objective and methods: To determine the frequency of a low-renin phenotype in a prospective cohort of hypertensive patients with adrenal adenomas and to evaluate the clinical response to aldosterone-targeted therapy across baseline aldosterone categories. Low-renin phenotype was defined as suppressed renin (PRA <1.0 ng/mL/ h or DRC <10 μIU/mL). Among these patients, plasma aldosterone concentration (PAC) was categorized as 5–10 ng/dL (Group 1), 10–15 ng/dL (Group 2), and >15 ng/dL (Group 3). Patients with suppressed renin were treated with MR antagonists or adrenalectomy and followed longitudinally using PAMO/PASO criteria. Results: Low renin was present in 47% (138/290) of hypertensive patients. Increasing aldosterone levels were associated with higher systolic blood pressure (SBP), resistant hypertension, higher antihypertensive treatment burden, lower potassium, and reduced eGFR (p-trend <0.001). After a mean follow-up of 24±18 months (n = 121), aldosterone-targeted therapy (75% medical, 25% surgical) led to significant reductions in SBP (-18, -26, and -30 mmHg across Groups 1–3; all p < 0.001), decreased medication and significant increases in renin (all p < 0.001), irrespective of aldosterone category. Conclusions: Nearly half of hypertensive patients with adrenal incidentalomas exhibit suppressed renin levels associated with greater blood pressure burden and favorable response to aldosterone-targeted therapy, even in lower aldosterone levels categories. These findings support systematic renin assessment in hypertensive patients with incidental adrenal adenomas and provide a rationale for testing aldosterone-targeted therapy in broader hypertensive populations beyond adrenal adenomas | |
| dc.identifier.citation | European Journal of Internal Medicine, (2026), Article 107042 | |
| dc.identifier.doi | https://doi.org/10.1016/j.ejim.2026.107042 | |
| dc.identifier.issn | 0953-6205 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-6081-1468 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12254/7674 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.rights | Atribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL) | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/cl/ | |
| dc.subject | Adrenal adenomas | |
| dc.subject | Low renin hypertension | |
| dc.subject | Aldosterone dysregulation | |
| dc.subject | Hypertension | |
| dc.subject | Primary aldosteronism | |
| dc.subject | Mineralocorticoid receptor | |
| dc.subject | Adrenal incidentaloma | |
| dc.title | Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study | |
| dc.type | Article |
Archivos
Bloque original
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- 1-s2.0-S095362052600347X-main.pdf
- Tamaño:
- 804.88 KB
- Formato:
- Adobe Portable Document Format
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 347 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: